HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $82 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintains an $82 price target.
June 08, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Legend Biotech and maintains an $82 price target.
The reiterated Buy rating and maintained $82 price target by HC Wainwright & Co. analyst Mitchell Kapoor indicates a positive outlook for Legend Biotech. This news is likely to have a positive short-term impact on LEGN's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100